Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-02
2009-06-23
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07550433
ABSTRACT:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4677195 (1987-06-01), Hewick et al.
patent: 5006333 (1991-04-01), Saifer et al.
patent: 5278065 (1994-01-01), D'Andrea et al.
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5292654 (1994-03-01), Yoshimura et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5441868 (1995-08-01), Lin
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5547933 (1996-08-01), Lin
patent: 5580853 (1996-12-01), Sytkowski
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5677280 (1997-10-01), Barrett et al.
patent: 5683983 (1997-11-01), Barrett et al.
patent: 5747446 (1998-05-01), Sytkowski
patent: 5756349 (1998-05-01), Lin
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5919758 (1999-07-01), Sytkowski
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5955422 (1999-09-01), Lin
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 6048971 (2000-04-01), Sytkowski et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 6083913 (2000-07-01), Dower et al.
patent: 6103879 (2000-08-01), Chaovapong et al.
patent: 6107272 (2000-08-01), Sytkowski
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6121238 (2000-09-01), Dower et al.
patent: 6153407 (2000-11-01), Sytkowski et al.
patent: 6221608 (2001-04-01), Middleton et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: 6333031 (2001-12-01), Olsson et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6465430 (2002-10-01), Dower et al.
patent: 6489293 (2002-12-01), Sytkowski et al.
patent: 6498155 (2002-12-01), Luengo et al.
patent: 6506362 (2003-01-01), Dower et al.
patent: 6531121 (2003-03-01), Brines et al.
patent: 6552008 (2003-04-01), Duffy et al.
patent: 6552167 (2003-04-01), Rose
patent: 6576235 (2003-06-01), Williams et al.
patent: 6583272 (2003-06-01), Bailon
patent: 6660843 (2003-12-01), Feige et al.
patent: 6703480 (2004-03-01), Balu
patent: 6777387 (2004-08-01), Greenwald et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 6784154 (2004-08-01), Westenfelder
patent: 6858630 (2005-02-01), Luengo et al.
patent: 2002/0037841 (2002-03-01), Papadimitriou et al.
patent: 2002/0052317 (2002-05-01), Itri et al.
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: 2002/0160013 (2002-10-01), Olsson et al.
patent: 2002/0169128 (2002-11-01), Sigounas et al.
patent: 2002/0177166 (2002-11-01), Guthridge et al.
patent: 2003/0009018 (2003-01-01), Maeda et al.
patent: 2003/0012777 (2003-01-01), Sherman et al.
patent: 2003/0050269 (2003-03-01), Escary
patent: 2003/0104988 (2003-06-01), Brines et al.
patent: 2003/0120045 (2003-06-01), Bailon
patent: 2003/0125262 (2003-07-01), Kiessling et al.
patent: 2003/0134798 (2003-07-01), Brines et al.
patent: 2003/0166249 (2003-09-01), Williams et al.
patent: 2003/0191291 (2003-10-01), Kochendoerfer et al.
patent: 2004/0062746 (2004-04-01), Martinez et al.
patent: 2004/0126361 (2004-07-01), Saifer et al.
patent: 2004/0136952 (2004-07-01), Bhaskaran et al.
patent: 2005/0014240 (2005-01-01), Sherman et al.
patent: 2005/0176627 (2005-08-01), Cerami et al.
patent: 0 400 472 (1990-12-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 92/16555 (1992-10-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 96/40749 (1996-12-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 98/25965 (1998-06-01), None
patent: WO 00/07629 (2000-02-01), None
patent: WO 00/12587 (2000-03-01), None
patent: WO 00/24770 (2000-05-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/33881 (2000-06-01), None
patent: WO 01/38342 (2001-05-01), None
patent: WO 01/59078 (2001-08-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/065988 (2002-08-01), None
patent: WO 03/002716 (2003-01-01), None
patent: WO 2004/014424 (2004-02-01), None
patent: WO 2004/030617 (2004-04-01), None
patent: WO 2004/060299 (2004-07-01), None
patent: WO 2004/060300 (2004-07-01), None
patent: WO-2004/100997 (2004-11-01), None
patent: WO-2004/101600 (2004-11-01), None
patent: WO 2004/101606 (2004-11-01), None
patent: WO 2004/101611 (2004-11-01), None
patent: WO 2004/108070 (2004-12-01), None
Abuchowski, A.,et al., “Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase,” J. Biol. Chem, vol. 252, pp. 3582-3586 (1977).
Beauchamp, C.O., et al., “A new procedure for the synthesis of polytheylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal Biochem., vol. 131, pp. 25-33 (1983).
Chen, R.H., et al., “Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)”, Biochem. Biophys. Acta., vol. 660, pp. 293-298 (1981).
El-Sayed et al., “Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium”, Pharm. Res., 2001, 18:23-28.
Francis, G.E., et al., “PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques”, Int. J. Hematol, vol. 68, pp. 1-18 (1998).
Gestwicki et al., “Influencing receptor-ligand binding mechanims with multivalent ligant architecture”, J. Amer. Chem. Soc., 2002, 124:14922-14933.
Greenwald, R.B., et al. (2003) Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. Bioconjug. Chem. 14:395-403.
Greenwald, R.B., et al. (2003) Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217-250.
Johnson et al., “Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1”, Biochemistry 37: 3699-3710 (1998).
Johnson, D.L., et al., “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity”, Chem. Biol., vol. 4, pp. 939-950 (1997).
Kita, Y., et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma”, Dr. Des. Deliv. vol. 6, pp. 157-167 (1990).
Klajnert et al., “Dendrimers: properties and applications”, Acta Biochimica Polonica, 2001, 48:199-208.
Knauf, M.J., et al., “Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers”, J. Biol. Chem., vol. 263, pp. 15064-15070 (1988).
Lee, J.W., et al., “Reduction of azides to primary amines in substrates bearing labile ester functionality. Synthesis of a PEG-solubilized, “Y”-shaped iminodiacetic acid reagent for preparation of folate-tethered drugs”, Org. Lett., vol. 1, pp. 179-181 (1999).
Ramakrishnan et al., “Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoitin after single and multiple doses in healthy volunteers”, J. Clin. Pharmacol., 2004, 44:991-992.
Saifer, M.G., et al., “Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol”, Adv. Exp. Med. Biol. vol. 366, pp. 377-387 (1994).
Sasaki, et al., “Carbohydrate structure of erythro
Duliege Anne-Marie
Leuther Kerstin
Naso Robert Barnett
Stead Richard
Woodburn Kathryn
Affymax, Inc.
Darby & Darby P.C.
Russel Jeffrey E
LandOfFree
Erythropoietin receptor peptide formulations and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin receptor peptide formulations and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin receptor peptide formulations and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132668